1.
Gan To Kagaku Ryoho
; 36(5): 769-72, 2009 May.
Artigo
em Japonês
| MEDLINE
| ID: mdl-19461175
RESUMO
We examined 51 patients treated with Capecitabine for metastatic breast cancer. 51 patients achieved a 30.8% response rate, 59.6% a clinical benefit rate(59.6%)and 7.2 M of time to disease progression, as previously reported. Capecitabine therapy, single agent or combination therapy, should be considered a treatment of choice for metastatic breast cancer with certain response and general tolerability.